

Beraprost as initial pharmacologic treatment for pulmonary hypertension related to left to right shunt congenital heart disease: A preliminary study

Shirley Ferlina Lasmono, Mahrus A. Rachman, Ketut Alit Utamayasa, Teddy Ontoseno

Airlangga University, Indonesia



Abstract

Pulmonary arterial hypertension is a common complication of uncorrected left-to-right shunt congenital heart disease. Beraprost have been used widely to treat pulmonary arterial hypertension in adult. However, the efficacy of the drug in Indonesian children has not been investigated. This study aim is to evaluate the efficacy of Beraprostin treating pulmonary arterial hypertension related to left-to-right shunt congenital heart disease. A randomized control trial was used in this study between April to September 2017 in Cardiology outpatient clinic of Dr. Soetomo General Hospital. Subjects aged 2-12 years with pulmonary arterial hypertension randomly received Beraprost 0.35mcg/kg eight hourly for 12 weeks. Efficacy was evaluated by echocardiography and adverse effect was monitored. Data were analyzed by statistical of tware using t-test and Mann Whitney test with significance level set to 0.05. All procedures were approved by hospital ethics committee and registered at the Clinical Trials.gov. Twenty two children were recruited in to the study. Resolution of Beraprost in decreasing pulmonary arterial pressure was -21.32 ± 11.06 mmHg ($p = 0.034$). Adverse effects reported were headache. As conclusion, Beraprostis effective and safe as initial pharmacologic treatment in treating pulmonary arterial hypertension related to left to right shunt congenital heart disease.

Keywords: Beraprost, pulmonaryarterialhypertension, congenitalheartdefect, left-to-rightshunt

Speaker Publications:

1. "Duchenne muscular dystrophy: overview and future challenges"; Neurological news. / 2017 / 17(3) /pp 144-149

[17th International Conference on Pediatrics and Pediatric Cardiology](#); Webinar; June 18-19, 2020.

Abstract Citation:

Shirley Ferlina Lasmono, Beraprost as initial pharmacologic treatment for pulmonary hypertension related to left to right shunt congenital heart disease: A preliminary study, Pediatric Cardiology 2020, 17th International Conference on Pediatrics and Pediatric Cardiology; Webinar; June 18-19, 2020 (<https://pediatriccardiology.conferenceseries.com/europe/abstract/2020/beraprost-as-initial-pharmacologic-treatment-for-pulmonary-hypertension-related-to-left-to-right-shunt-congenital-heart-disease-a-preliminary-study>)



Biography:

Shirley Ferlina Lasmono is a pediatrician graduated from Pediatric department of University Airlangga Surabaya. She is working as a pediatrician in Madura Island to improve the child health there. Shirley has published some papers during the residency and has been serving as a speaker and committee in some medical seminar.